Roche NT-proBNP CHF Test Launch Expected By Jan. Pending FDA Approval

Roche expects its NT-proBNP N-terminal pro-B-type natriuretic peptide diagnostic for chronic heart failure to cost less than competitor BioSite's Triage point of care test